OBJECTIVE: Preservation of renal function is the major benefit of partial over radical nephrectomy.
We evaluated patients undergoing minimally invasive partial nephrectomy (MIPN) to better understand factors predicting long-term renal function.
METHODS: We identified 358 patients who underwent MIPN for confirmed renal cell carcinoma between 1998 and 2011 with a serum creatinine level at least 1 year postoperatively. Exposure variables included demographic, clinical, and perioperative information. The primary outcome was clinically significant progression of chronic kidney disease (CKD) class, defined as estimated glomerular filtration rate (eGFR) decreasing from >60 to < 60, from 30 to 60 to < 30, or from 15 to 30 to < 15. Bivariate and multivariate analyses were performed.
RESULTS: Median follow-up was 39 months. Only 7 patients had a solitary kidney. A total of 47 patients (13%) had CKD class progression. The estimates for remaining free of CKD class progression at 5, 7, and 10 years were 86.98%, 75.45%, and 53.54%, respectively. On multivariate analysis, lower preoperative eGFR (odds ratio [OR] = 0.97, 95% CI: 0.96-0.98), larger tumor size (OR = 1.22, 95% CI: 1.01-1.48), and longer ischemia time (OR = 1.03, 95% CI: 1.01-1.05) were associated with CKD class progression.
CONCLUSIONS: Clinically significant progression of CKD occurs in a minority of patients 5 years after MIPN, but in almost one-half, it occurs 10 years after surgery. Lower preoperative eGFR and larger tumor size are associated with greater incidence of CKD progression. Longer ischemia time, even when most patients had 2 kidneys and when controlling for other factors, nonetheless increased the risk of CKD progression, although this may be a marker of other unmeasured variables.
Written by:
Mukkamala A, He C, Weizer AZ, Hafez KS, Miller DC, Montgomery JS, Bitzer M, Stuart Wolf J Jr. Are you the author?
Department of Urology, University of Michigan Hospitals and Health Centers, Ann Arbor, MI; Division of Nephrology, University of Michigan Hospitals and Health Centers, Ann Arbor, MI.
Reference: Urol Oncol. 2014 May 17. pii: S1078-1439(14)00154-9.
doi: 10.1016/j.urolonc.2014.04.012
PubMed Abstract
PMID: 24846342
UroToday.com Renal & Vascular Diseases Section
